Sector Expert: Kevin DeGeeter

Ladenburg Thalmann

Image: Kevin DeGeeter

Kevin DeGeeter is a director at Ladenburg Thalmann & Co. Inc. He is responsible for equity research coverage of personalized medicine and medical device companies with market capitalizations between $50 million and $5 billion. His coverage focuses on molecular diagnostics and medical equipment used in oncology, cardiovascular disease and infectious disease, as well as related research markets. Prior to joining Ladenburg Thalmann he was an analyst at Oppenheimer & Co., with responsibility for small-cap molecular diagnostic and biotechnology stocks. He has 10 years of buyside and sellside research experience, including positions with J. P. Morgan, PaineWebber, Natexis Bleichroeder and Manning & Napier Advisors. DeGeeter received a bachelor's degree in economics from Colgate University.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • Mesoblast Ltd.


Recent Interviews

Diagnostics and Stem Cells Power Productive Portfolios: Kevin DeGeeter (5/30/13)

New medical tests can be moneymakers for small- and mid-cap companies: They save insurers the pain of paying more to treat maladies and save patients from unnecessary treatments. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Director Kevin DeGeeter of Ladenburg, Thalmann & Co. makes his case for diagnostics companies with compelling ideas in the realms of cancer, cardiovascular and surgical testing. He also has one interesting stem cell idea to share.

Testing, Testing: Analyst Kevin DeGeeter on Five Good Bets in Cancer Diagnostics (11/29/12)

Because margins in diagnostics and life sciences tools tend to decline over time, the industry is all about scale. The goal is either to develop novel products or tests with high profit potential, or to acquire them. Another strategy is to develop economies of scale through consolidation. In this interview with The Life Sciences Report, Kevin DeGeeter, senior analyst and director of healthcare research for Ladenburg Thalmann, has singled out five important companies with exciting business models or products.

Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter (5/10/12)

Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation. In this exclusive interview with The Life Sciences Report, Kevin DeGeeter, senior analyst with Ladenburg Thalmann & Co. Inc., shares the names of a select group of companies with good prospects, focusing on those targeting "sweet spots" in personalized medicine.

Recent Quotes

"MESO is now well positioned to potentially conclude partnering discussions for MPC-06-ID in the coming months; we reiterate our Buy rating."

— Kevin DeGeeter, Ladenburg Thalmann (5/10/16)
more >

"New results increased our confidence in MESO's Phase 3 aGVHD study."

— Kevin DeGeeter, Ladenburg Thalmann (2/23/16)
more >

"We expect MSB, following restructuring, to be funded through fiscal Q4/17."

— Kevin DeGeeter, Ladenburg Thalmann (12/17/15)
more >

"Professor Joanne Kurtzberg discussed aGHVD treatments including MSB's."

— Kevin DeGeeter, Ladenburg Thalmann (12/8/15)
more >

"MSB's Phase 3 study in GvHD is likely to meet its primary endpoint."

— Kevin DeGeeter, Ladenburg Thalmann (12/4/15)
more >

"The first commercial launch should alter MSB's investment profile."

— Kevin DeGeeter, Ladenburg Thalmann (11/25/15)
more >

"MSB's Phase 2 study in rheumatoid arthritis is enrolling 48 patients."

— Kevin DeGeeter, Ladenburg Thalmann (11/24/15)
more >

"MSB announced Japan recommended approval of JR-031 for acute GvHD."

— Kevin DeGeeter, Ladenburg Thalmann (9/8/15)
more >

more comments

"MSB's upcoming RA data readout is a low-risk/high-reward catalyst."

— Kevin DeGeeter, Ladenburg Thalmann (8/17/15)
more >

"MSB's autoimmune disease programs pipeline has partnership potential."

— Kevin DeGeeter, Ladenburg Thalmann (6/30/15)
more >

"Data presented at the ADA meeting could serve as a catalyst for MSB."

— Kevin DeGeeter, Ladenburg Thalmann (6/4/15)
more >

"MSB's agreement with Celgene further solidifies its leadership in regenerative medicine."

— Kevin DeGeeter, Ladenburg Thalmann (4/13/15)
more >

"Teva's meeting significantly derisks MSB's cardiovascular franchise."

— Kevin DeGeeter, Ladenburg Thalmann (12/12/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.